Identity
KPV denotes the tripeptide Lys-Pro-Val, corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone. A key primary study is Dalmasso et al. (2008). This article concerns KPV as a component, not the combined activity of Halo or KLOW Pro.
Cell-uptake and signaling experiments
Dalmasso and colleagues studied intestinal epithelial cell lines and Jurkat immune cells. They investigated PepT1-mediated uptake and inflammatory signaling, including NF-kappaB, MAPK and cytokine readouts. Transporter-mediated entry in these experiments does not establish the bioavailability of the labeled tablet product.
Mouse inflammatory models
The same paper evaluated DSS- and TNBS-associated mouse colitis models and reported changes in experimental inflammatory outcomes. The model-specific findings are not evidence of human treatment efficacy.
Component, label and measured evidence
KPV component research does not establish blend synergy, safety or efficacy. KLOW Pro retains its labeled BPC-157 20 mg, TB-500 20 mg, GHK-Cu 30 mg and KPV 10 mg composition; it is distinct from standard KLOW. Halo label quantities and measured analytical quantities must remain separately identified. The article supplies research context and does not determine lot identity or release status.
Related
- research-safety-basicsarticle
- ghk cu kpv halo blend 60mgproduct
- ghk cu kpv tb 500 bpc 157 80mgproduct
- kpv 500mcg tabletsproduct
References
- Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. [primary; intestinal and immune cell cultures plus DSS/TNBS mouse models]PMID: 18061177DOI: 10.1053/j.gastro.2007.10.026
More questions?
Ask our Support Team — they can answer follow-up questions about this topic, COAs, storage, or anything else in the research library.
Tap the "Chat with us" tab on the right edge of any page.